<p>In the last three months, 5 analysts have published ratings on SI-BONE (NASDAQ:SIBN), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<p>Analysts have set 12-month price targets for SI-BONE, revealing an average target of $24.2, a high estimate of $27.00, and a low estimate of $21.00. This current average reflects an increase of 6.37% from the previous average price target of $22.75. </p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769522472_0_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="price target chart" width="700" height="500" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769522472_0_0.png"/></p>

<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of SI-BONE among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mathew Blackman</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Buy</td>
<td>$21.00</td>
<td>-</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Caitlin Roberts</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$27.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$27.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Drew Ranieri</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>

<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to SI-BONE. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of SI-BONE compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of SI-BONE's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into SI-BONE's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p>Stay up to date on SI-BONE analyst ratings.</p>
<p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p>
<h2>All You Need to Know About SI-BONE</h2>
<p>SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.</p>
<h3>SI-BONE: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, SI-BONE showcased positive performance, achieving a revenue growth rate of <strong>20.61%</strong> as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-9.38%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> SI-BONE's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-2.67%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> SI-BONE's ROA excels beyond industry benchmarks, reaching <strong>-1.96%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.21</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>

SIBN

<p>In the past three months, five analysts have provided ratings on SI-BONE (NASDAQ:SIBN), showing a mix of bullish to bearish sentiments. The average 12-month price target is $24.2, up 6.37% from the previous target. Analysts have raised their ratings, with notable increases from firms like Truist Securities and Canaccord Genuity. SI-BONE has reported a revenue growth of 20.61% and maintains a net margin of -9.38%. The company also shows strong financial health with a low debt-to-equity ratio of 0.21. Analyst ratings are crucial for investors, reflecting expert insights into stock performance.</p>

A Glimpse Into The Expert Outlook On SI-BONE Through 5 Analysts